A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

NCT06853457 | Completed

• 1 other identifier: IIT-2023-983
• Study Type: observational
• Target: 257
• Locations: 0 countries
• Sites: N/A

Brief Summary

To develop and validate a CT-based transfer learning radiomics model for predicting response to initial TAE in GEP-NETLM patients and compare its performance with traditional radiomics and clinical models.

Conditions

Neuroendocrine Tumors, NET

Outcome Measures

Primary Outcomes (1)

• The efficacy of TAE

  Complete multiphase contrast-enhanced CT images were collected preoperatively and postoperatively. The efficacy of TAE was assessed based on RECIST 1.1 criteria. Patients were classified as objective responders (those achieving complete response \[CR\] or partial response \[PR\]) or non-responders (those with stable disease \[SD\] or progressive disease \[PD\]) through evaluation of target lesions.

  Within one month prior and 4-6 weeks following the initial TAE.

Study Arms (2)

training set

The training set consisted of patients from January 2014 to December 2020.

testing set

the testing set included patients from January 2021 to September 2022.

Eligibility Criteria

• Age: 18 Years - 78 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study retrospectively included gastroenteropancreatic neuroendocrine tumors liver metastasis patients who receive initial transarterial embolization from January 2014 to September 2022 at The First Affiliated Hospital of Sun Yat-sen University.

You may qualify if:

• (a) Clinical diagnosed as gastroenteropancreatic neuroendocrine tumor liver metastases; (b) Received initial transarterial embolization therapy; (c) Underwent multi-phase ceCT scans pre-TAE (≤1 month) and post-TAE (4-6 weeks).

You may not qualify if:

• (a) Neuroendocrine carcinoma (NEC) or other malignancies. (b) Received other liver metastasis treatments. (c) Lack of Multi-phase ceCT scans records. (d) CT images with artifacts or no visible lesions.

Sponsors & Collaborators

• First Affiliated Hospital, Sun Yat-Sen University: lead

MeSH Terms

Conditions

Neuroendocrine Tumors

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: February 23, 2025
• First Posted: March 3, 2025
• Study Start: January 1, 2014
• Primary Completion: September 30, 2022
• Study Completion: September 1, 2024
• Last Updated: March 3, 2025

Record last verified: 2025-02